Lisa Anne Bero, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Lisa Anne Bero, PhD

Professor, Department of Clinical Pharmacy and Institute for Health Policy Studies, UCSF

bero@medicine.ucsf.edu

Phone: (415) 476-1067 (voice)
Box 0613, UCSF

View on UCSF Profiles


Education

Michigan State University, East Lansing, MI, B.S. (honors), 1980, Physiology/Philosophy
Duke University, Durham, NC, Ph.D., 1987, Pharmacology
NIDA Postdoctoral Fellowship, University of California, San Francisco (UCSF), 1987-88, Pharmacology
Pew Health Policy Fellowship, UCSF, 1988-90, Health Policy
1987-1988 NIDA Postdoctoral Fellow, University of California, San Francisco, CA (UCSF)


Professional Experience

  • 1988-1992
    Pew Fellowship, Institute for Health Policy Studies, UCSF
  • 1994-present
    Co-Director, San Francisco Cochrane Center
  • 6/00-present
    Vice Chair, Department of Clinical Pharmacy, UCSF
  • 6/01-present
    Professor, Dept. Clinical Pharmacy/ Institute for Health Policy Studies/ Center for Tobacco Control Research and Education, UCSF

Honors & Awards

  • 1994-1992
    Special Consultant to the European Union Committee on Technology Assessment
  • 1992
    Best article published in 1996 in the Intl J Technology Assessment in Health Care
  • 1992
    Special consultant to the World Bank for a background paper on Tobacco Control Policies
  • 2000-2001, 2002
    Special Advisor to World Health Organization

Selected Publications

  1. Siler K, Lee K, Bero L. Reply to Margalida and Colomer: Science should strive to prevent mistakes, not corrections. Proc Natl Acad Sci U S A. 2015 Mar 31; 112(13):E1512.
    View on PubMed
  2. Hill SR, Bero L, McColl G, Roughead E. Expensive medicines: ensuring objective appraisal and equitable access. Bull World Health Organ. 2015 Jan 1; 93(1):4.
    View on PubMed
  3. Siler K, Lee K, Bero L. Measuring the effectiveness of scientific gatekeeping. Proc Natl Acad Sci U S A. 2015 Jan 13; 112(2):360-5.
    View on PubMed
  4. Forsyth SR, Odierna DH, Krauth D, Bero LA. Conflicts of interest and critiques of the use of systematic reviews in policymaking: an analysis of opinion articles. Syst Rev. 2014; 3(1):122.
    View on PubMed
  5. Bero L. Bias related to funding source in statin trials. BMJ. 2014; 349:g5949.
    View on PubMed
  6. Fox DM, Bero L. Systematic reviews: perhaps "the answer to policy makers' prayers"? Environ Health Perspect. 2014 Oct; 122(10):A262-3.
    View on PubMed
  7. Magrini N, Robertson J, de Joncheere K, Bero L. On WHO's essential medicines process and transparency. BMJ. 2014; 349:g5637.
    View on PubMed
  8. Formoso G, Marata AM, Magrini N, Bero L. A clearer view of evidence in treating macular degeneration: off-label policies and independent research. Cochrane Database Syst Rev. 2014; 9:ED000090.
    View on PubMed
  9. Schroll JB, Abdel-Sattar M, Bero L. The Food and Drug Administration reports provided more data but were more difficult to use than the European Medicines Agency reports. J Clin Epidemiol. 2015 Jan; 68(1):102-7.
    View on PubMed
  10. Bero L. What is in a name? Nonfinancial influences on the outcomes of systematic reviews and guidelines. J Clin Epidemiol. 2014 Nov; 67(11):1239-41.
    View on PubMed
  11. Mahady SE, Schlub T, Bero L, Moher D, Tovey D, George J, Craig JC. Side effects are incompletely reported among systematic reviews in gastroenterology. J Clin Epidemiol. 2015 Feb; 68(2):144-53.
    View on PubMed
  12. Tovey D, Churchill R, Bero L. Evidence based medicine: looking forward and building on what we have learnt. BMJ. 2014; 349:g4508.
    View on PubMed
  13. Anglemyer A, Horvath HT, Bero L. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. Cochrane Database Syst Rev. 2014; 4:MR000034.
    View on PubMed
  14. Coralic Z, Kanzaria HK, Bero L, Stein J. Staff Perceptions of an On-site Clinical Pharmacist Program in an Academic Emergency Department after One Year. West J Emerg Med. 2014 Mar; 15(2):205-10.
    View on PubMed
  15. Krauth D, Woodruff TJ, Bero L. Instruments for assessing risk of bias and other methodological criteria: Krauth et al. Respond. Environ Health Perspect. 2014 Mar; 122(3):A67.
    View on PubMed
  16. Krauth D, Anglemyer A, Philipps R, Bero L. Nonindustry-sponsored preclinical studies on statins yield greater efficacy estimates than industry-sponsored studies: a meta-analysis. PLoS Biol. 2014 Jan; 12(1):e1001770.
    View on PubMed
  17. Alexander PE, Bero L, Montori VM, Brito JP, Stoltzfus R, Djulbegovic B, Neumann I, Rave S, Guyatt G. World Health Organization recommendations are often strong based on low confidence in effect estimates. J Clin Epidemiol. 2014 Jun; 67(6):629-34.
    View on PubMed
  18. Bero LA. Why the Cochrane risk of bias tool should include funding source as a standard item. Cochrane Database Syst Rev. 2013; 12:ED000075.
    View on PubMed
  19. Neltner TG, Alger HM, O'Reilly JT, Krimsky S, Bero LA, Maffini MV. Conflicts of interest in approvals of additives to food determined to be generally recognized as safe: out of balance. JAMA Intern Med. 2013 Dec 9-23; 173(22):2032-6.
    View on PubMed
  20. Chahal HS, St Fort N, Bero L. Availability, prices and affordability of essential medicines in Haiti. J Glob Health. 2013 Dec; 3(2):020405.
    View on PubMed

Go to UCSF Profiles, powered by CTSI